Indian Journal of Psychological Medicine
  Home | About Us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Contact | Advertise | Submission | Login 
Users Online: 1400 
Wide layoutNarrow layoutFull screen layoutHome Print this page Email this page Small font sizeDefault font sizeIncrease font size


 
 Table of Contents    
CASE REPORT
Year : 2018  |  Volume : 40  |  Issue : 2  |  Page : 191-192  

Lurasidone induced thrombocytopenia: Is it a signal of drug induced myelosuppression?


1 Department of Pharmacology, Sri Aurobindo Medical College and PGI, Indore, Madhya Pradesh, India
2 Department of Psychiatry, Sri Aurobindo Medical College and PGI, Indore, Madhya Pradesh, India

Date of Web Publication1-Mar-2018

Correspondence Address:
Mohammad Rafi
Department of Pharmacology, Sri Aurobindo Medical College and PGI, Indore - 453 555, Madhya Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJPSYM.IJPSYM_374_17

Rights and Permissions
   Abstract 


The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application Lurasidone (Latuda, Sunovion Pharmaceuticals), an atypical antipsychotic, for the treatment of schizophrenia in adolescents 13–17 years of age. Lurasidone was previously indicated in the U.S. for the treatment of adults with schizophrenia and major depressive episodes with bipolar I disorder as monotherapy. We present a case of a 29-year-old male patient who was hospitalized with thrombocytopenia (WHO grade-3 toxicity) (unlabeled) along with extrapyramidal disorder, gastritis, and hyperprolactinemia within 2–3 months of initiation of tablet lurasidone 80 mg/day (Lurasid, Intas Pharmaceuticals) in bipolar depression. Dechallenge was found to be positive in three reactions except hyperprolactinemia (outcome unknown) during hospital stay. The terms anemia and leukopenia are well labeled/listed with the drug literatures of lurasidone. Thus, this case presents a strong probability of lurasidone to cause myelosuppression/bone marrow depression.

Keywords: Bone marrow depression, lurasidone, myelosuppression, thrombocytopenia


How to cite this article:
Rafi M, Goyal C, Reddy P, Reddy S. Lurasidone induced thrombocytopenia: Is it a signal of drug induced myelosuppression?. Indian J Psychol Med 2018;40:191-2

How to cite this URL:
Rafi M, Goyal C, Reddy P, Reddy S. Lurasidone induced thrombocytopenia: Is it a signal of drug induced myelosuppression?. Indian J Psychol Med [serial online] 2018 [cited 2020 Jan 25];40:191-2. Available from: http://www.ijpm.info/text.asp?2018/40/2/191/226504




   Introduction Top


First approved in October 2010 for the treatment of schizophrenia in adults, lurasidone is a benzisothiazol-derivative, second-generation (atypical) antipsychotic. Similar to other atypical antipsychotics, it antagonizes dopamine D2 receptors, but also serotonin 5-HT2A and 5-HT7 receptors.[1] Several antipsychotics are now FDA approved in the management of bipolar depression including quetiapine and lurasidone.[2] Lurasidone was well-tolerated, and commonly observed adverse reactions (incidence ≥5% and at least twice the rate for placebo) were akathisia, extrapyramidal symptoms, and somnolence.[3]


   Case Report Top


A 29-year-old male patient with bipolar depression was hospitalized with chief complaints of tremors, involuntary movements of limbs and upper body, vomiting and burning sensation in stomach for 2 weeks. He was on tablet lurasidone (Lurasid) 80 mg once a day for 2½ months started by some clinical psychiatrist. In suspect of drug-induced extrapyramidal disorder and gastritis, lurasidone was discontinued from the day of hospitalization. On the same day, blood sample for routine complete blood count and serum prolactin was collected. Hemoglobin was found to be 15.3 g% and total white blood cells were 5300/cmm whereas platelets were only 37,000. Serum prolactin level was also raised with 26.93 ng/ml. Thrombocytopenia and hyperprolactinemia too were now suspected to be drug-induced. Capsule of esomeprazole with domperidone, tablet risperidone, and tablet trihexyphenidyl was started to manage the reactions after which gastritis and extrapyramidal disorder started subsiding. After a week, again test for platelet counts was performed which showed improvement with platelet count of 1.83 lacs/cmm. The outcome of hyperprolactinemia was unknown as the patient was discharged from the hospital.


   Discussion Top


In our case, dechallenge was positive, and thus, the causal association of thrombocytopenia with lurasidone as per WHO-UMC causality assessment scale was found probable. Leukopenia, neutropenia, and anemia were noted in Phase 2 and 3 controlled and uncontrolled studies; however, the incidence of occurrence for these is too low to estimate frequencies.[4] When the WHO-UMC database was accessed for lurasidone, there are 52 reports under blood and lymphatic system disorders till date. Out of these, there are 6 reports of thrombocytopenia (including this only report from India), 2 reports of platelet disorder and a report of bone marrow failure.[5] Moreover, a total number of 2148 reports of adverse reactions to various system organ classes were reported from WHO-UMC member countries to Vigibase which are very less as compared to various established drugs available in the market for decades.[5]

Therefore, clinicians should also monitor hematological adverse effects at regular intervals after initiation of therapy and report the same to the nearest pharmacovigilance center established under Pharmacovigilance Programme of India. This will help in finding the actual frequency and magnitude of such serious adverse effects and thus improve patients' safety by timely taking proper regulatory decisions by drug regulators throughout the globe.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Sunovion Pharmaceuticals Inc. Latuda (lurasidone hydrochloride) package insert. Marlborough, Massachusetts: Sunovion Pharmaceuticals Inc.; 2013.  Back to cited text no. 1
    
2.
Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 13th Ed. New Delhi: Mc Graw Hill (India) Private Ltd.; 2015 p. 498.  Back to cited text no. 2
    
3.
Bawa R, Scarff JR. Lurasidone: A new treatment option for bipolar depression - A review. Innov Clin Neurosci 2015;12:21-3.  Back to cited text no. 3
    
4.
Anon; 2017. Available from: https://www.medicines.org.uk/emc/medicine/29125#UNDESIRABLE_EFFECTS. [Last accessed 2017 Aug 21].  Back to cited text no. 4
    
5.
Available from: http://www.vigiaccess.org. [Last accessed on 2017 Aug 21].  Back to cited text no. 5
    




 

Top
 
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Report
   Discussion
    References

 Article Access Statistics
    Viewed537    
    Printed5    
    Emailed0    
    PDF Downloaded39    
    Comments [Add]    

Recommend this journal